RE: Revisit Vulpes Investment Report as they Head to San Francisco with more positive data ,looking forward to a phase 3 trial ,more deals for Glymab Therapeutics and more data from the Modify trial30 Dec 2025 13:55
Agree with Berm on reservations around how much value an investor should place on such a very old report. Probably posted half a dozen times or more already, overtaken by subsequent company presentations and for me, it’s barrel-scraping and it’s much better to wait for Q1 news updates.